Evidence map›Paper›PMID 39585410›Full record

ArticleBiotechnology letters2024

Computer-aided rational design of a mRNA vaccine against Guanarito mammarenavirus.

Mohibullah Shah, Asifa Sarfraz, Muhammad Shehroz, Asia Perveen, Samavia Jaan, Aqal Zaman, Umar Nishan, Arlindo A Moura, Riaz Ullah, Zafar Iqbal and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohibullah Shah *Department of Biochemistry, Bahauddin Zakariya University, Multan, 66000, Punjab, Pakistan. mohib@bzu.edu.pk.ORCID http://orcid.org/0000-0001-6126-7102
Asifa Sarfraz *Department of Biochemistry, Bahauddin Zakariya University, Multan, 66000, Punjab, Pakistan.
Muhammad ShehrozDepartment of Bioinformatics, Kohsar University Murree, Murree, 47150, Pakistan.
Asia PerveenDepartment of Biochemistry, Bahauddin Zakariya University, Multan, 66000, Punjab, Pakistan.
Samavia JaanDepartment of Biochemistry, Bahauddin Zakariya University, Multan, 66000, Punjab, Pakistan.
Aqal ZamanDepartment of Microbiology & Molecular Genetics, Bahauddin Zakariya University, Multan, 66000, Pakistan.
Umar NishanDepartment of Chemistry, Kohat University of Science & Technology, Kohat, Pakistan.
Arlindo A MouraDepartment of Animal Science, Federal University of Ceara, Fortaleza, Brazil.
Riaz UllahDepartment of Pharmacognosy College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Zafar IqbalDepartment of Surgery, College of Medicine, King Saud University, P.O. Box 7805, Riyadh, 11472, Kingdom of Saudi Arabia.
Mohamed A IbrahimDepartment of Pharmaceutics, College of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia.

Funding

King Saud University RSP2024R171
6 · The paper itself

Abstract

purposeGuanarito mammarenavirus (GTOV) is a highly pathogenic virus that leads to Venezuelan hemorrhagic fever (VHF). Despite being a severe disease, there are currently no commercially available drugs or vaccines for its prevention.

methodsHere we computationally formulated a mRNA vaccine construct (VC) from the genome of GTOV to produce immunity against its infections. Two proteins, namely zinc-finger motif protein (NP_899220.1), and nucleocapsid protein (NP_899211.1) were screened as potential candidates for downstream analysis.

resultsWe determined the T and B cell epitopes of the candidate proteins. The resulting epitopes were analyzed, and the best epitopes were utilized in the formation of the peptide vaccine construct. The secondary and tertiary structures of the peptide construct were predicted and validated. Docking was conducted to check the binding energy of the designed peptide vaccine with the human immune receptors, namely TLR2 and TLR4. Our designed vaccine showed stable interactions with the HLA molecules, as verified through normal mode and MD simulation analysis. The immune simulation results indicated a positive immune response against the construct. A potentially stable mRNA vaccine was formulated by adding of sequences such as the Kozak, Goblin 5' UTR, tPA-signal peptide, MITD, 3' UTRs, and a poly(A) tail to the peptide vaccine construct. Lastly, the expression probability of the mRNA vaccine was confirmed in the expression system of E. coli strain K12.

conclusionThe designed vaccine showed the potential to elicit an immune response against the GTOV infection; however, experimental validation is recommended to verify the in-silico findings of this study.

Indexed as

ArenaviridaeViral VaccinesComputer-Aided DesignEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMolecular Docking SimulationmRNA VaccinesToll-Like Receptor 2Toll-Like Receptor 4Vaccines, SubunitVaccines, SyntheticEpitopes, B-LymphocyteEpitopes, T-LymphocytemRNA VaccinesTLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4Vaccines, SubunitVaccines, SyntheticViral VaccinesArenavirusEpitopeGuanarito mammarenavirusImmunoinformaticsPeptide vaccine

Identifiers

PMID39585410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.